Molecular mechanisms of endocrine disruption in estrogen dependent processes

Endocrine Disruptors: Effects on Male and Female Reproductive Systems, Second Edition

Volumn , Issue , 2004, Pages 217-247

  Bigsby, Robert M ^a   Mercado Feliciano, Minerva ^a   Mubiru, Josephine ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882811277     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (206)

1. Bigsby, R., Chapin, R.E., Daston, G.P., et al., Evaluating the effects of endocrine disruptors on endocrine function during development, Environ. Health Perspect., 107, 613, 1999.
2. Adams, N.R., Permanent infertility in ewes exposed to plant oestrogens, Aust. Vet. J., 67, 197, 1990.
3. Adams, N.R., and Sanders, M.R., Persistent infertility in ewes after prolonged exposure to oestradiol-17 beta, J. Reprod. Fertil., 84, 373, 1988.
4. Hickey, J.J., The Perigrine Falcon Populations: Their Biology and Decline, University of Wisconsin Press, Madison, WI, 1969.
5. Wurster, C.F.J., and Wingate, D.B., DDT residues and declining reproduction in the Bermuda petrel, Science, 159, 979, 1968.
6. Robinson, J., Residues of organochlorine insecticides in dead birds in the United Kingdom, Chem. Ind., 47, 1974, 1967.
7. Risebrough, R.W., Menzel, D.B., Martin, D.J.J., et al., DDT residues in Pacific sea birds: a persistent insecticide in marine food chains, Nature, 216, 589, 1967.
8. Ratcliffe, D.A., Decrease in eggshell weight in certain birds of prey, Nature, 215, 208, 1967.
9. Bitman, J., Cecil, H.C., Harris, S.J., et al., Estrogenic activity of o, p’-DDT in the mammalian uterus and avian oviduct, Science, 162, 371, 1968.
10. Lundholm, C.D., DDE-induced eggshell thinning in birds: effects of p, p’-DDE on the calcium and prostaglandin metabolism of the eggshell gland, Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol., 118, 113, 1997.
11. Herbst, A.L., Ulfelder, H., and Poskanzer, D.C., Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women, N. Engl. J. Med., 284, 878, 1971.
12. Melnick, S., Cole, P., Anderson, D., et al., Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix, N. Engl. J. Med., 316, 514, 1987.
13. Hertz, R., The estogen problem: Retrospect and prospect, in: Estrogen in the Environment II, McLachlan, J.A., Ed., Elsevier, New York, 1985, 1.
14. Shapiro, S., and Slone, D., The effects of exogenous female hormones on the fetus, Epidemiol. Rev., 1, 110, 1979.
15. Kaufman, R.H., Adam, E., Binder, G.L., et al., Upper genital tract changes and pregnancy outcome in offspring exposed in utero to diethylstilbestrol, Am. J. Obstet. Gynecol., 137, 299, 1980.
16. Newbold, R.R., Bullock, B.C., and McLachlan, J.A., Uterine adencarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis, Cancer Res., 50, 7677, 1990.
17. Newbold, R.R., Banks, E.P., Bullock, B., et al., Uterine adenocarcinoma in mice treated neonatally with genistein, Cancer Res., 61, 4325, 2001.
18. Wilcox, A.J., Baird, D.D., Weinberg, C.R., et al., Fertility in men exposed prenatally to diethylstilbestrol, N. Engl. J. Med., 332, 1411, 1995.
19. Newbold, R.R., Hanson, R.B., Jefferson, W.N., et al., Proliferative lesions and reproductive tract tumors in male descendants of mice exposed developmentally to diethylstilbestrol, Carcinogenesis, 21, 1355, 2000.
20. Strohsnitter, W.C., Noller, K.L., Hoover, R.N., et al., Cancer risk in men exposed in utero to diethylstilbestrol, J. Natl. Cancer Inst., 93, 545, 2001.
21. Hulka, B.S., Liu, E.T., and Lininger, R.A., Steroid hormones and risk of breast cancer, Cancer, 74, 1111, 1994.
22. Kuller, L.H., The etiology of breast cancer-from epidemiology to prevention, Public Health Rev., 23, 157, 1995.
23. Persson, I., Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings, J. Steroid Biochem. Mol. Biol., 74, 357, 2000.
24. Eden, J., Progestins and breast cancer, Am. J. Obstet. Gynecol., 188, 1123, 2003.
25. Williams, R.J., Johnson, A.C., Smith, J.J., et al., Steroid estrogens profiles along river stretches arising from sewage treatment works discharges, Environ. Sci. Technol., 37, 1744, 2003.
26. Sumpter, J.P., Xenoendorine disrupters-environmental impacts, Toxicol. Lett., 102-103, 337, 1998.
27. Aherne, G.W., and Briggs, R., The relevance of the presence of certain synthetic steroids in the aquatic environment, J. Pharm. Pharmacol., 41, 735, 1989.
28. McMartin, K.E., Kennedy, K.A., Greenspan, P., et al., Diethylstilbestrol: a review of its toxicity and use as a growth promotant in food-producing animals, J. Environ. Pathol. Toxicol., 1, 279, 1978.
29. Clarkson, T.W., Environmental contaminants in the food chain, Am. J. Clin. Nutr., 61, 682S, 1995.
30. Soto, A. M., Sonnenschein, C., Murray, M. K., et al., Estrogenic plasticizers and antioxidants. In: Hormonally active agents in food, Eisenbrand, G., Ed., Wiley-Vch, Weinheim, Germany, 1998, 128.
31. Kurzer, M.S., and Xu, X., Dietary phytoestrogens, Annu. Rev. Nutr., 17, 353, 1997.
32. U.S.E.P.A., Draft Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds. Volume 2: Sources of Dioxinlike Compounds in the United States, http://cfpub.epa.gov/ncea/cfm/part1and2.cfm? ActType=default, 2000.
33. McKenna, N.J., Lanz, R.B., and O’Malley, B.W., Nuclear receptor coregulators: cellular and molecular biology, Endocr. Rev., 20, 321, 1999.
34. Katzenellenbogen, B.S., and Katzenellenbogen, J.A., Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer, Breast Cancer Res., 2, 335, 2000.
35. Nilsson, S., Makela, S., Treuter, E., et al., Mechanisms of estrogen action, Physiol. Rev., 81, 1535, 2001.
36. Shiau, A.K., Barstad, D., Loria, P.M., et al., The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen, Cell, 95, 927, 1998.
37. Shiau, A.K., Barstad, D., Radek, J.T., et al., Structural characterization of a subtypeselective ligand reveals a novel mode of estrogen receptor antagonism, Nat. Struct. Biol., 9, 359, 2002.
38. Kushner, P.J., Agard, D.A., Greene, G.L., et al., Estrogen receptor pathways to AP-1, J. Steroid Biochem. Mol. Biol., 74, 311, 2000.
39. Safe, S., Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions, Vitam. Horm., 62, 231, 2001.
40. Safe, S., and McDougal, A., Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers, Int. J. Oncol., 20, 1123, 2002.
41. Ohtake, F., Takeyama, K., Matsumoto, T., et al., Modulation of oestrogen receptor signalling by association with the activated dioxin receptor, Nature, 423, 545, 2003.
42. Anstead, G.M., Carlson, K.E., and Katzenellenbogen, J.A., The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site, Steroids, 62, 268, 1997.
43. Blair, R.M., Fang, H., Branham, W.S., et al., The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands, Toxicol. Sci., 54, 138, 2000.
44. Kuiper, G.G., Carlsson, B., Grandien, K., et al., Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta, Endocrinology, 138, 863, 1997.
45. Bolger, R., Wiese, T.E., Ervin, K., et al., Rapid screening of environmental chemicals for estrogen receptor binding capacity, Environ. Health Perspect., 106, 551, 1998.
46. Vakharia, D.D., and Gierthy, J.F., Use of a combined human liver microsome-estrogen receptor binding assay to assess potential estrogen modulating activity of PCB metabolites, Toxicol. Lett., 114, 55, 2000.
47. Perez, P., Pulgar, R., Olea-Serrano, F., et al., The estrogenicity of bisphenol A-related diphenylalkanes with various substituents at the central carbon and the hydroxy groups, Environ. Health Perspect., 106, 167, 1998.
48. Andersen, H.R., Andersson, A.M., Arnold, S.F., et al., Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals, Environ. Health Perspect., 107 Suppl. 1, 89, 1999.
49. Kuiper, G.G., Lemmen, J.G., Carlsson, B., et al., Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta, Endocrinology, 139, 4252, 1998.
50. Kim, H.S., Han, S.Y., Yoo, S.D., et al., Potential estrogenic effects of bisphenol-A estimated by in vitro and in vivo combination assays, J. Toxicol. Sci., 26, 111, 2001.
51. Martin, M.B., Reiter, R., Pham, T., et al., Estrogen-like activity of metals in MCF-7 breast cancer cells, Endocrinology, 144, 2425, 2003.
52. Oh, S.M., and Chung, K.H., Estrogenic activities of Ginkgo biloba extracts, Life Sci., 74, 1325, 2004.
53. Harris, H.A., Bapat, A.R., Gonder, D.S., et al., The ligand binding profiles of estrogen receptors alpha and beta are species dependent, Steroids, 67, 379, 2002.
54. Steinmetz, R., Young, P.C., Caperell-Grant, A., et al., Novel estrogenic action of the pesticide residue beta-hexachlorocyclohexane in human breast cancer cells, Cancer Res., 56, 5403, 1996.
55. Coosen, R., and van Velsen, F.L., Effects of the ß-isomer of hexachlorocyclohexane on estrogen-sensitive human mammary tumor cells, Toxicol. Appl. Pharmacol., 101, 310, 1989.
56. Fang, H., Tong, W., Shi, L.M., et al., Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens, Chem. Res. Toxicol., 14, 280, 2001.
57. Shi, L.M., Fang, H., Tong, W., et al., QSAR models using a large diverse set of estrogens, J. Chem. Inf. Comput. Sci., 41, 186, 2001.
58. Steinmetz, R., Brown, N.G., Allen, D.L., et al., The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo, Endocrinology, 138, 1780, 1997.
59. Steinmetz, R., Mitchner, N.A., Grant, A., et al., The xenoestrogen bisphenol A induces growth, differentiation, and c-fos gene expression in the female reproductive tract, Endocrinology, 139, 2741, 1998.
60. Long, X., Burke, K.A., Bigsby, R.M., et al., Effects of the xenoestrogen bisphenol A on expression of vascular endothelial growth factor (VEGF) in the rat, Exp. Biol. Med. (Maywood), 226, 477, 2001.
61. Kupfer, D., and Bulger, W.H., Metabolic activation of pesticides with proestrogenic activity, Fed. Proc., 46, 1864, 1987.
62. Bulger, W.H., Feil, V.J., and Kupfer, D., Role of hepatic monoxygenases in generation estrogenic metabolites from methoxychlor and from its identified contaminants, Mol. Pharmacol., 27, 115, 1985.
63. Welshons, W.V., Nagel, S.C., Thayer, K.A., et al., Low-dose bioactivity of xenoestrogens in animals: fetal exposure to low doses of methoxychlor and other xenoestrogens increases adult prostate size in mice, Toxicol. Ind. Health, 15, 12, 1999.
64. Yoshihara, S., Makishima, M., Suzuki, N., et al., Metabolic activation of bisphenol A by rat liver S9 fraction, Toxicol. Sci., 62, 221, 2001.
65. Yoshihara, S., Mizutare, T., Makishima, M., et al., Potent estrogenic metabolites of bisphenol A and bisphenol B formed by rat liver S9 fraction: their structures and estrogenic potency, Toxicol. Sci., 2003.
66. Routledge, E.J., White, R., Parker, M.G., et al., Differential effects of xenoestrogens on coactivator recruitment by ERalpha and ERbeta, J. Biol. Chem., 2000.
67. Hall, J.M., McDonnell, D.P., and Korach, K.S., Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements, Mol. Endocrinol., 16, 469, 2002.
68. Watanabe, H., Suzuki, A., Kobayashi, M., et al., Similarities and differences in uterine gene expression patterns caused by treatment with physiological and non-physiological estrogens, J. Mol. Endocrinol., 31, 487, 2003.
69. Adachi, T., Koh, K.B., Tainaka, H., et al., Toxicogenomic difference between diethylstilbestrol and 17beta-estradiol in mouse testicular gene expression by neonatal exposure, Mol. Reprod. Dev., 67, 19, 2004.
70. Larkin, P., Sabo-Attwood, T., Kelso, J., et al., Gene expression analysis of largemouth bass exposed to estradiol, nonylphenol, and p, p’-DDE, Comp. Biochem. Physiol. B. Biochem. Mol. Biol., 133, 543, 2002.
71. Naciff, J.M., Jump, M.L., Torontali, S.M., et al., Gene expression profile induced by 17alpha-ethynyl estradiol, bisphenol A, and genistein in the developing female reproductive system of the rat, Toxicol. Sci., 68, 184, 2002.
72. Toppari, J., Larsen, J.C., Christiansen, P., et al., Male reproductive health and envrionmental xenoestrogens, Environ. Health Perspect., 104, 741, 1996.
73. Brock, J.W., Melnyk, L.J., Caudill, S.P., et al., Serum levels of several organochlorine pesticides in farmers correspond with dietary exposure and local use history, Toxicol. Ind. Health, 14, 275, 1998.
74. Helzlsouer, K.J., Alberg, A.J., Huang, H.Y., et al., Serum concentrations of organochlorine compounds and the subsequent development of breast cancer, Cancer Epidemiol. Biomarkers Prev., 8, 525, 1999.
75. Dorgan, J.F., Brock, J.W., Rothman, N., et al., Serum organochlorine pesticides and PCBs and breast cancer risk: results from a prospective analysis (USA), Cancer Causes Control, 10, 1, 1999.
76. Chun, T.Y., Gregg, D., Sarkar, D.K., et al., Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth, Proc. Natl. Acad. Sci. U.S.A., 95, 2325, 1998.
77. Ulrich, E.M., Caperell-Grant, A., Hites, R.A., et al., Environmentally relevant xenoestrogen tissue concentrations correlated to biological response in mice, Environ. Health Perspect., 108, 973, 2000.
78. Cos, P., De, B.T., Apers, S., et al., Phytoestrogens: recent developments, Planta Med., 69, 589, 2003.
79. Schmitt, E., Dekant, W., and Stopper, H., Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues, Toxicol. in vitro, 15, 433, 2001.
80. Maggiolini, M., Bonofiglio, D., Marsico, S., et al., Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells, Mol. Pharmacol., 60, 595, 2001.
81. Rowlands, J.C., Berhow, M.A., and Badger, T.M., Estrogenic and antiproliferative properties of soy sapogenols in human breast cancer cells in vitro, Food Chem. Toxicol., 40, 1767, 2002.
82. Messina, M.J., Persky, V., Setchell, K.D., et al., Soy intake and cancer risk: a review of the in vitro and in vivo data, Nutr. Cancer, 21, 113, 1994.
83. Messina, M.J., and Loprinzi, C.L., Soy for breast cancer survivors: a critical review of the literature, J. Nutr., 131, 3095S, 2001.
84. Burow, M.E., Boue, S.M., Collins-Burow, B.M., et al., Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta, J. Clin. Endocrinol. Metab., 86, 1750, 2001.
85. Willson, T.M., and Moore, J.T., Genomics versus orphan nuclear receptors-a halftime report, Mol. Endocrinol., 16, 1135, 2002.
86. Suetsugi, M., Su, L., Karlsberg, K., et al., Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors, Mol. Cancer. Res., 1, 981, 2003.
87. Wormke, M., Stoner, M., Saville, B., et al., Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes, FEBS Lett., 478, 109, 2000.
88. Connor, K., Ramamoorthy, K., Moore, M., et al., Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships, Toxicol. Appl. Pharmacol., 145, 111, 1997.
89. Fernandez, P., and Safe, S., Growth inhibitory and antimitogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in T47D human breast cancer cells, Toxicol. Lett., 61, 185, 1992.
90. Harper, N., Wang, X., Liu, H., et al., Inhibition of estrogen-induced progesterone receptor in MCF-7 human breast cancer cells by aryl hydrocarbon (Ah) receptor agonists, Mol. Cell. Endocrinol., 104, 47, 1994.
91. Krishnan, V., and Safe, S., Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: quantitative structure-activity relationships, Toxicol. Appl. Pharmacol., 120, 55, 1993.
92. Moore, M., Mustain, M., Daniel, K., et al., Antiestrogenic activity of hydroxylated polychlorinated biphenyl congeners identified in human serum, Toxicol. Appl. Pharmacol., 142, 160, 1997.
93. Taylor, H.S., The role of HOX genes in human implantation, Hum. Reprod. Update, 6, 75, 2000.
94. Benson, G.V., Lim, H., Paria, B.C., et al., Mechanisms of reduced fertility in Hoxa-10 mutant mice: uterine homeosis and loss of maternal Hoxa-10 expression, Development, 122, 2687, 1996.
95. Gendron, R.L., Paradis, H., Hsieh-Li, H.M., et al., Abnormal uterine stromal and glandular function associated with maternal reproductive defects in Hoxa-11 null mice, Biol. Reprod., 56, 1097, 1997.
96. Block, K., Kardana, A., Igarashi, P., et al., In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing mullerian system, FASEB J., 14, 1101, 2000.
97. Couse, J.F., Dixon, D., Yates, M., et al., Estrogen receptor-alpha knockout mice exhibit resistance to the developmental effects of neonatal diethylstilbestrol exposure on the female reproductive tract, Dev. Biol., 238, 224, 2001.
98. Miller, C., Degenhardt, K., and Sassoon, D.A., Fetal exposure to DES results in deregulation of Wnt7a during uterine morphogenesis, Nat. Genet., 20, 228, 1998.
99. Parr, B.A., and McMahon, A.P., Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a, Nature, 395, 707, 1998.
100. Ehrlich, M., Expression of various genes is controlled by DNA methylation during mammalian development, J. Cell. Biochem., 88, 899, 2003.
101. Li, S., Washburn, K.A., Moore, R., et al., Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus, Cancer Res., 57, 4356, 1997.
102. Li, S., Ma, L., Chiang, T., et al., Promoter CpG methylation of Hox-a10 and Hoxa11 in mouse uterus not altered upon neonatal diethylstilbestrol exposure, Mol. Carcinog., 32, 213, 2001.
103. Hayashi, N., Hasegawa, K., Komine, A., et al., Estrogen-induced cell transformation and DNA adduct formation in cultured Syrian hamster embryo cells, Mol. Carcinog., 16, 149, 1996.
104. Thomas, R.D., and Roy, D., Stilbene estrogen produces higher levels of mitochondrial DNA adducts than nuclear DNA adducts in the target organ of cancer (liver) of male Sprague Dawley rats, Oncol. Rep., 8, 1035, 2001.
105. Atkinson, A., and Roy, D., In vivo DNA adduct formation by bisphenol A, Environ. Mol. Mutagen., 26, 60, 1995.
106. Roy, D., and Liehr, J.G., Estrogen, DNA damage and mutations, Mutat. Res., 424, 107, 1999.
107. Das, S.K., Taylor, J.A., Korach, K.S., et al., Estrogenic responses in estrogen receptoralpha deficient mice reveal a distinct estrogen signaling pathway, Proc. Natl. Acad. Sci. USA, 94, 12786, 1997.
108. Das, S.K., Tan, J., Raja, S., et al., Estrogen targets genes involved in protein processing, calcium homeostasis, and Wnt signaling in the mouse uterus independent of estrogen receptor-alpha and -beta, J. Biol. Chem., 275, 28834, 2000.
109. Bigsby, R.M., unpublished data, 2004.
110. Collins-Burow, B.M., Burow, M.E., Duong, B.N., et al., Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms, Nutr. Cancer, 38, 229, 2000.
111. Kaneuchi, M., Sasaki, M., Tanaka, Y., et al., Resveratrol suppresses growth of Ishikawa cells through down-regulation of EGF, Int. J. Oncol., 23, 1167, 2003.
112. Kaneuchi, M., Sasaki, M., Tanaka, Y., et al., Quercetin regulates growth of Ishikawa cells through the suppression of EGF and cyclin D1, Int. J. Oncol., 22, 159, 2003.
113. Pietras, R.J., and Szego, C.M., Endometrial cell calcium and oestrogen action, Nature, 253, 357, 1975.
114. Pietras, R.J., and Szego, C.M., Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells, Nature, 265, 69, 1977.
115. Pietras, R.J., Nemere, I., and Szego, C.M., Steroid hormone receptors in target cell membranes, Endocrine, 14, 417, 2001.
116. Filardo, E.J., Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer, J. Steroid Biochem. Mol. Biol., 80, 231, 2002.
117. Migliaccio, A., Castoria, G., Di, D.M., et al., Sex steroid hormones act as growth factors, J. Steroid Biochem. Mol. Biol., 83, 31, 2002.
118. Migliaccio, A., Castoria, G., Di, D.M., et al., Src is an initial target of sex steroid hormone action, Ann. NY Acad. Sci., 963, 185, 2002.
119. Enan, E., and Matsumura, F., Activation of c-neu tyrosine kinase by o, p’-DDT and ß-HCH in cell-free and intact cell preparations from MCF-7 human breast cancer cells, J. Biochem. Toxicol., 12, 83, 1998.
120. Hatakeyama, M., and Matsumura, F., Correlation between the activation of Neu tyrosine kinase and promotion of foci formation induced by selected organochlorine compounds in the MCF-7 model system, J. Biochem. Mol. Toxicol., 13, 296, 1999.
121. Hatakeyama, M., Zou, E., and Matsumura, F., Comparison of the characteristic of estrogenic action patterns of beta-HCH and heregulin beta1 in MCF-7 human breast cancer cells, J. Biochem. Mol. Toxicol., 16, 209, 2002.
122. Frigo, D.E., Duong, B.N., Melnik, L.I., et al., Flavonoid phytochemicals regulate activator protein-1 signal transduction pathways in endometrial and kidney stable cell lines, J. Nutr., 132, 1848, 2002.
123. Frigo, D.E., Tang, Y., Beckman, B.S., et al., Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway, Carcinogenesis, 2003.
124. Akiyama, T., Ishida, J., Nakagawa, S., et al., Genistein, a specific inhibitor of tyrosinespecific protein kinases, J. Biol. Chem., 262, 5592, 1987.
125. Walker, H.E., Pacold, E.M., Perisic, O., et al., Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine, Mol. Cell, 6, 909, 2000.
126. Guo, Y., Hendrickx, A.G., Overstreet, J.W., et al., Endocrine biomarkers of early fetal loss in cynomolgus macaques (Macaca fascicularis) following exposure to dioxin, Biol. Reprod., 60, 707, 1999.
127. Drenth, H.J., Bouwman, C.A., Seinen, W., et al., Effects of some persistent halogenated environmental contaminants on aromatase (CYP19) activity in the human choriocarcinoma cell line JEG-3, Toxicol. Appl. Pharmacol., 148, 50, 1998.
128. Letcher, R.J., van, H.I., Drenth, H.J., et al., Cytotoxicity and aromatase (CYP19) activity modulation by organochlorines in human placental JEG-3 and JAR choriocarcinoma cells, Toxicol. Appl. Pharmacol., 160, 10, 1999.
129. Moran, F.M., VandeVoort, C.A., Overstreet, J.W., et al., Molecular target of endocrine disruption in human luteinizing granulosa cells by 2,3,7,8-tetrachlorodibenzo-pdioxin: inhibition of estradiol secretion due to decreased 17alpha-hydroxylase/17,20-lyase cytochrome P450 expression, Endocrinology, 144, 467, 2003.
130. Akingbemi, B.T., Sottas, C.M., Koulova, A.I., et al., Inhibition of testicular steroidogenesis by the xenoestrogen bisphenol A is associated with reduced pituitary LH secretion and decreased steroidogenic enzyme gene expression in rat Leydig cells, Endocrinology, 2003.
131. Adlercreutz, H., Bannwart, C., Wahala, K., et al., Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens, J. Steroid Biochem. Mol. Biol., 44, 147, 1993.
132. Pelissero, C., Lenczowski, M.J., Chinzi, D., et al., Effects of flavonoids on aromatase activity, an in vitro study, J. Steroid Biochem. Mol. Biol., 57, 215, 1996.
133. Mak, P., Cruz, F.D., and Chen, S., A yeast screen system for aromatase inhibitors and ligands for androgen receptor: yeast cells transformed with aromatase and androgen receptor, Environ. Health Perspect., 107, 855, 1999.
134. Le, B.J.C., Champavier, Y., Chulia, A.J., et al., Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells, Life Sci, 66, 1281, 2000.
135. Whitehead, S.A., and Lacey, M., Phytoestrogens inhibit aromatase but not 17betahydroxysteroid dehydrogenase (HSD) type 1 in human granulosa-luteal cells: evidence for FSH induction of 17beta-HSD, Hum. Reprod., 18, 487, 2003.
136. Almstrup, K., Fernandez, M.F., Petersen, J.H., et al., Dual effects of phytoestrogens result in u-shaped dose-response curves, Environ. Health Perspect., 110, 743, 2002.
137. Raftogianis, R., Creveling, C., Weinshilboum, R., et al., Estrogen metabolism by conjugation, J. Natl. Cancer Inst. Monogr., 27, 113, 2000.
138. Lakhani, N.J., Venitz, J., Figg, W.D., et al., Pharmacogenetics of estrogen metabolism and transport in relation to cancer, Curr. Drug Metab., 4, 505, 2003.
139. Lee, A.J., Cai, M.X., Thomas, P.E., et al., Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms, Endocrinology, 144, 3382, 2003.
140. Paria, B.C., Lim, H., Das, S.K., et al., Molecular signaling in uterine receptivity for implantation, Semin. Cell Dev. Biol., 11, 67, 2000.
141. Zhu, B.T., and Conney, A.H., Functional role of estrogen metabolism in target cells: review and perspectives, Carcinogenesis, 19, 1, 1998.
142. Xiao, L., and Becker, J.B., Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release, Synapse, 29, 379, 1998.
143. Yager, J.D., Endogenous estrogens as carcinogens through metabolic activation, J. Natl. Cancer Inst. Monogr., 27, 67, 2000.
144. Liehr, J.G., Is estradiol a genotoxic mutagenic carcinogen?, Endocr. Rev., 21, 40, 2000.
145. Rogan, E.G., Badawi, A.F., Devanesan, P.D., et al., Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer, Carcinogenesis, 24, 697, 2003.
146. Bradlow, H.L., Telang, N.T., Sepkovic, D.W., et al., 2-hydroxyestrone: the ‘good’ estrogen, J. Endocrinol., 150, Suppl:S259, 1996.
147. Kristensen, V.N., and Borresen-Dale, A.L., Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism, Mutat. Res., 462, 323, 2000.
148. Mitrunen, K., and Hirvonen, A., Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism, Mutat. Res., 544, 9, 2003.
149. Jan, S.T., Devanesan, P.D., Stack, D.E., et al., Metabolic activation and formation of DNA adducts of hexestrol, a synthetic nonsteroidal carcinogenic estrogen, Chem. Res. Toxicol., 11, 412, 1998.
150. Carmichael, P.L., Mills, J.J., Campbell, M., et al., Mechanisms of hormonal carcinogenesis in the p53+/-hemizygous knockout mouse: studies with diethylstilbestrol, Toxicol. Pathol., 29 Suppl., 155, 2001.
151. Green, M., Thomas, R., Gued, L., et al., Inhibition of DES-induced DNA adducts by diallyl sulfide: implications in liver cancer prevention, Oncol. Rep., 10, 767, 2003.
152. Atkinson, A., and Roy, D., In vitro conversion of environmental estrogenic chemical bisphenol A to DNA binding metabolite(s), Biochem. Biophys. Res. Commun., 210, 424, 1995.
153. Atkinson, A., and Roy, D., In vivo DNA adduct formation by bisphenol A, Environ. Mol. Mutagen., 26, 60, 1995.
154. Nakagawa, Y., and Tayama, S., Metabolism and cytotoxicity of bisphenol A and other bisphenols in isolated rat hepatocytes, Arch. Toxicol., 74, 99, 2000.
155. Elsby, R., Maggs, J.L., Ashby, J., et al., Comparison of the modulatory effects of human and rat liver microsomal metabolism on the estrogenicity of bisphenol A: implications for extrapolation to humans, J. Pharmacol. Exp. Ther., 297, 103, 2001.
156. Kim, Y.H., Kim, C.S., Park, S., et al., Gender differences in the levels of bisphenol A metabolites in urine, Biochem. Biophys. Res. Commun., 312, 441, 2003.
157. Denison, M.S., and Nagy, S.R., Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals, Annu. Rev. Pharmacol. Toxicol., 43, 309, 2003.
158. Hakkola, J., Pasanen, M., Pelkonen, O., et al., Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells, Carcinogenesis, 18, 391, 1997.
159. Whitlock, J.P.J., Induction of cytochrome P4501A1, Annu. Rev. Pharmacol. Toxicol., 39, 103, 1999.
160. Mimura, J., and Fujii-Kuriyama, Y., Functional role of AhR in the expression of toxic effects by TCDD, Biochim. Biophys. Acta., 1619, 263, 2003.
161. Horn, T.L., Reichert, M.A., Bliss, R.L., et al., Modulations of P450 mRNA in liver and mammary gland and P450 activities and metabolism of estrogen in liver by treatment of rats with indole-3-carbinol, Biochem. Pharmacol., 64, 393, 2002.
162. Wang, H.W., Chen, F.W., and Ueng, T.H., Induction of cytochromes P-450 1A1 and 1B1 by motorcycle exhaust particulate in human breast cancer MCF-7 cells, J. Toxicol. Environ. Health A, 65, 1401, 2002.
163. Spink, B.C., Hussain, M.M., Katz, B.H., et al., Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells by indirubin, Biochem. Pharmacol., 66, 2313, 2003.
164. van, D.M.B., Sanderson, J.T., van, D.B.M., et al., Effects of several dioxin-like compounds on estrogen metabolism in the malignant MCF-7 and nontumorigenic MCF-10A human mammary epithelial cell lines, Toxicol. Appl. Pharmacol., 190, 241, 2003.
165. Tritscher, A.M., Seacat, A.M., Yager, J.D., et al., Increased oxidative DNA damage in livers of 2,3,7,8-tetrachlorodibenzo-p-dioxin treated intact but not ovariectomized rats, Cancer Lett., 98, 219, 1996.
166. Wyde, M.E., Wong, V.A., Kim, A.H., et al., Induction of hepatic 8-oxo-deoxyguanosine adducts by 2,3,7,8-tetrachlorodibenzo-p-dioxin in Sprague-Dawley rats is female-specific and estrogen-dependent, Chem. Res. Toxicol., 14, 849, 2001.
167. Jeuken, A., Keser, B.J., Khan, E., et al., Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits, J. Agric. Food. Chem., 51, 5478, 2003.
168. Henry, E.C., Kende, A.S., Rucci, G., et al., Flavone antagonists bind competitively with 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) to the aryl hydrocarbon receptor but inhibit nuclear uptake and transformation, Mol. Pharmacol., 55, 716, 1999.
169. Bjeldanes, L.F., Kim, J.Y., Grose, K.R., et al., Aromatic hydrocarbon responsivenessreceptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin, Proc. Natl. Acad. Sci. USA, 88, 9543, 1991.
170. Yang, X.F., Wang, N.P., Lu, W.H., et al., Effects of Ginkgo biloba extract and tanshinone on cytochrome P-450 isozymes and glutathione transferase in rats, Acta Pharmacol. Sin., 24, 1033, 2003.
171. Ciolino, H.P., Daschner, P.J., and Yeh, G.C., Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor, Cancer Res., 58, 5707, 1998.
172. Casper, R.F., Quesne, M., Rogers, I.M., et al., Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity, Mol. Pharmacol., 56, 784, 1999.
173. Ashida, H., Fukuda, I., Yamashita, T., et al., Flavones and flavonols at dietary levels inhibit a transformation of aryl hydrocarbon receptor induced by dioxin, FEBS Lett., 476, 213, 2000.
174. Shimada, T., Yamazaki, H., Mimura, M., et al., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther., 270, 414, 1994.
175. Yokose, T., Doy, M., Taniguchi, T., et al., Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues, Virchows Arch., 434, 401, 1999.
176. Honkakoski, P., Sueyoshi, T., and Negishi, M., Drug-activated nuclear receptors CAR and PXR, Ann. Med., 35, 172, 2003.
177. Kliewer, S.A., The nuclear pregnane X receptor regulates xenobiotic detoxification, J. Nutr., 133, 2444S, 2003.
178. Carlberg, C., Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands, Recent Results Cancer Res., 164, 29, 2003.
179. Lindley, C., Hamilton, G., McCune, J.S., et al., The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes, Drug Metab. Dispos., 30, 814, 2002.
180. Zhang, W., Purchio, A., Chen, K., et al., In vivo activation of the human CYP3A4 promoter in mouse liver and regulation by pregnane X receptors, Biochem. Pharmacol., 65, 1889, 2003.
181. Dvorak, Z., Modriansky, M., Pichard-Garcia, L., et al., Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation, Mol. Pharmacol., 64, 160, 2003.
182. Engman, H.A., Lennernas, H., Taipalensuu, J., et al., CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies, J. Pharm. Sci., 90, 1736, 2001.
183. Elizondo, G., and Medina-Diaz, I.M., Induction of CYP3A4 by 1alpha,25-dyhydroxyvitamin D3 in HepG2 cells, Life Sci., 73, 141, 2003.
184. Luo, G., Cunningham, M., Kim, S., et al., CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes, Drug Metab. Dispos., 30, 795, 2002.
185. Niemi, M., Backman, J.T., Fromm, M.F., et al., Pharmacokinetic interactions with rifampicin: clinical relevance, Clin. Pharmacokinet., 42, 819, 2003.
186. Nallani, S.C., Glauser, T.A., Hariparsad, N., et al., Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate, Epilepsia, 44, 1521, 2003.
187. Gibson, G.G., el-Sankary, W., and Plant, N.J., Receptor-dependent regulation of the CYP3A4 gene, Toxicology, 181-182, 199, 2002.
188. Raucy, J., Warfe, L., Yueh, M.F., et al., A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system, J. Pharmacol. Exp. Ther., 303, 412, 2002.
189. Jones, S.A., Moore, L.B., Shenk, J.L., et al., The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution, Mol. Endocrinol., 14, 27, 2000.
190. Martin, H., Sarsat, J.P., de, W.I., et al., Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices, Pharm. Res., 20, 557, 2003.
191. Nallani, S.C., Goodwin, B., Maglich, J.M., et al., Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor, Drug Metab. Dispos., 31, 681, 2003.
192. Masuyama, H., Hiramatsu, Y., Kunitomi, M., et al., Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate pregnane X receptor-mediated transcription, Mol. Endocrinol., 14, 421, 2000.
193. Rosenfeld, W.E., Doose, D.R., Walker, S.A., et al., Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy, Epilepsia, 38, 317, 1997.
194. Ouellet, D., Hsu, A., Qian, J., et al., Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers, Br. J. Clin. Pharmacol., 46, 111, 1998.
195. Goodwin, B., Hodgson, E., D’Costa, D.J., et al., Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor, Mol. Pharmacol., 62, 359, 2002.
196. Drocourt, L., Ourlin, J.C., Pascussi, J.M., et al., Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes, J. Biol. Chem., 277, 25125, 2002.
197. Doose, D.R., Wang, S.S., Padmanabhan, M., et al., Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects, Epilepsia, 44, 540, 2003.
198. Hall, S.D., Wang, Z., Huang, S.M., et al., The interaction between St. John’s wort and an oral contraceptive, Clin. Pharmacol. Ther., 74, 525, 2003.
199. Markowitz, J.S., Donovan, J.L., DeVane, C.L., et al., Effect of St. John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme, JAMA, 290, 1500, 2003.
200. Suiko, M., Sakakibara, Y., and Liu, M.C., Sulfation of environmental estrogen-like chemicals by human cytosolic sulfotransferases, Biochem. Biophys. Res. Commun., 267, 80, 2000.
201. Shimizu, M., Ohta, K., Matsumoto, Y., et al., Sulfation of bisphenol A abolished its estrogenicity based on proliferation and gene expression in human breast cancer MCF-7 cells, Toxicol. in vitro, 16, 549, 2002.
202. Santen, R.J., Leszczynski, D., Tilson-Mallet, N., et al., Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways, Ann. N. Y. Acad. of Sci., 464, 126, 1986.
203. Raobaikady, B., Purohit, A., Chander, S.K., et al., Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bissulphamate, J. Steroid Biochem. Mol. Biol., 84, 351, 2003.
204. Kester, M.H., Bulduk, S., van, T.H., et al., Potent inhibition of estrogen sulfotransferase by hydroxylated metabolites of polyhalogenated aromatic hydrocarbons reveals alternative mechanism for estrogenic activity of endocrine disrupters, J. Clin. Endocrinol. Metab., 87, 1142, 2002.
205. Kirk, C.J., Bottomley, L., Minican, N., et al., Environmental endocrine disrupters dysregulate estrogen metabolism and Ca2+ homeostasis in fish and mammals via receptor-independent mechanisms, Comp. Biochem. Physiol. A Mol. Integr. Physiol., 135, 1, 2003.
206. Zhu, B.T., and Liehr, J.G., Inhibition of catechol O-methyltransferase-catalyzed Omethylation of 2-and 4-hydroxyestradiol by quercetin. Possible role in estradiolinduced tumorigenesis, J. Biol. Chem., 271, 1357, 1996.